Barriers to effective insulin treatment: The persistence of poor glycemic control in type 2 diabetes

Current Medical Research and Opinion

Volumn 27, Issue SUPPL. 3, 2011, Pages 13-20

  Ross, Stuart A ^a   Tildesley, Hugh D ^b   Ashkenas, John ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SCRIPT   (Canada)

Author keywords

Diabetes; Dose titration; Hypoglycemia; Insulin initiation; Intensive glycemic control; Treatment adherence; Weight gain

Indexed keywords

EXENDIN 4; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE;

ARTICLE; ATTITUDE TO HEALTH; BLOOD GLUCOSE MONITORING; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; GLYCEMIC CONTROL; HUMAN; HUMAN RELATION; HYPOGLYCEMIA; INJECTION; INSULIN TREATMENT; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; UNITED KINGDOM;

DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PATIENT COMPLIANCE;

EID: 81855194753     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.621416     Document Type: Article

References (51)

1. Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:S1-S201
2. Harris SB, Ekoe JM, Zdanowicz Y, et al. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70:90-7 (Pubitemid 41207652)
3. Braga M, Casanova A, Teoh H, et al. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol 2010;26:297-302
4. Ross SA, Yale J-F, Hahn J, et al. Baseline data from SOLVE imply initiation of insulin therapy remains delayed for many patients in Canadian primary care of type 2 diabetes. Abstract presented at the 70th Scientific Sessions of the American Diabetes Association; Orlando, FL, USA, June 23-29 2010. Abstract #2290-PO
5. Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010;56:e418-24
6. Akalin S, Berntorp K, Ceriello A, et al. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int J Clin Pract 2009;63:1421-5
7. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM 2000; 93:369-74 (Pubitemid 30386809)
8. Karter AJ, Parker MM, Adams AS, et al. Primary non-adherence to prescribed medications. J Gen Intern Med 2010;25:763
9. Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 2010;26:231-8
10. Rubin RR, Peyrot M, Kruger DF, et al. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ 2009; 35:1014-22
11. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAPDM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32
12. Kindmalm L, Melander A, Nilsson JL. Refill adherence of antihyperglycaemic drugs related to glucose control (HbA1c) in patients with type 2 diabetes. Acta Diabetol 2007;44:209-13 (Pubitemid 350132265)
13. Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5
14. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005;22:749-55 (Pubitemid 40805897)
15. Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ 2008;34:511-17
16. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9 (Pubitemid 43951158)
17. Leiter LA, Yale JF, Chiasson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92 (Pubitemid 43741134)
18. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med 2011;171:362-4
19. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
20. Chico A, Vidal-Rios P, Subira M, et al. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153-7 (Pubitemid 36929264)
21. Weber KK, Lohmann T, Busch K, et al. High frequency of unrecognized hypoglycaemias in patients with Type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes 2007;115:491-4 (Pubitemid 350056760)
22. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812 (Pubitemid 47555203)
23. Jensen MG, Hansen M, Brock B, et al. Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010;11:2027-35
24. Morris AD. Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ 2003;29:440-53 (Pubitemid 44858390)
25. Ross SA, Ekoe JM. Incretin agents in type 2 diabetes. Can Fam Physician 2010;56:639-48
26. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12 (Pubitemid 30609442)
27. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
28. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72 (Pubitemid 351831357)
29. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:34i-43i
30. Zhang CY, Sun AJ, Zhang SN, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a metaanalysis. Ann Med 2010;42:305-15
31. Riddle MC. Counterpoint: intensive glucose control and mortality in ACCORD-still looking for clues. Diabetes Care 2010;33:2722-4
32. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72
33. Tkac I. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: overview and metaanalysis of five trials. Diabetes Res Clin Pract 2009;86(Suppl 1):S57-62
34. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98
35. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-30
36. Benhalima K, Standl E, Mathieu C. The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. J Diabetes Complications 2011;25:202-7
37. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150:803-8
38. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-90
39. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:844-6
40. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
41. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-42
42. Meneghini L, Koenen C, Weng W, et al. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab 2007;9:902-13 (Pubitemid 47555212)
43. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6 (Pubitemid 37339502)
44. Hamaty M. Insulin treatment for type 2 diabetes: when to start, which to use. Cleve Clin J Med 2011;78:332-42
45. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47
46. Rakel RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Ther 2009;26:838-46
47. Jenkins N, Hallowell N, Farmer AJ, et al. Participants' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study. Diabet Med 2011;28:543-8
48. Simon ACR, DeVries HD. The future of basal insulin supplementation. Diabetes Technol Ther 2011;13(Suppl 1):S103-7
49. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to u-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 2011;13:592-5
50. Tildesley HD, Mazanderani AB, Ross SA. Effect of Internet therapeutic intervention on A1C levels in patients with type 2 diabetes treated with insulin. Diabetes Care 2010;33:1738-40
51. Tildesley HD, Mazanderani AB, Ross SA. Effect of Internet therapeutic intervention on HbA1C levels in patients with type 2 diabetes treated with insulin: results from a retrospective follow-up. Can J Diabetes 2011;35:250-3